Linden Capital Partners (“Linden”), a Chicago-based private equity firm focused exclusively on the healthcare industry, announces the completion of its acquisition of Alcresta Therapeutics, Inc. ( “Alcresta”), a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases, from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital. HealthQuest Capital subsequently re-invested in Alcresta and will continue as a minority shareholder and board member. Alcresta recently announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Read the full article: Linden Capital Partners Acquires Alcresta Therapeutics, Inc. //
Source: https://www.prnewswire.com/news-releases/linden-capital-partners-acquires-alcresta-therapeutics-inc-302086718.html